Skip to main content

5 Result(s)

within Gracia Martinez Remove this filter

and

  1. Article

    Open Access

    Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael… in Blood Cancer Journal (2023)

    Download PDF (385 KB) View Article

  2. Article

    Open Access

    Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-...

    Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael… in Blood Cancer Journal (2023)

    Download PDF (1487 KB) View Article

  3. No Access

    Article

    Acquired von willebrand syndrome secondary to monoclonal gammopathy of undetermined significance: long-term remission after treatment with bortezomib

    Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder that can precede the diagnosis of multiple myeloma. MGUS is characterized by the presence of a monoclonal paraprotein without...

    Artur Saldanha, Maria Eduarda Veiga… in Journal of Thrombosis and Thrombolysis (2023)

  4. No Access

    Article

    Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries

    In previous observational studies, we have separately characterized patients with multiple myeloma (MM) both from Latin America (LA) and from Asia. Here, we analyze these two datasets jointly, in order to asse...

    Vania T. M. Hungria, Jae Hoon Lee, Angelo Maiolino… in Annals of Hematology (2019)

  5. No Access

    Article

    Observational study of multiple myeloma in Latin America

    Relatively little is known about the outcomes of multiple myeloma in Latin America, a world region where incorporation of novel agents is generally slow. In the current retrospective-prospective study, we aime...

    Vania T. M. Hungria, Angelo Maiolino, Gracia Martinez… in Annals of Hematology (2017)